1. 2021 PACES expert consensus statement on the indications and management of cardiovascular implantable electronic devices in pediatric patients
- Author
-
Maully J. Shah, Michael J. Silka, Jennifer N. Avari Silva, Seshadri Balaji, Cheyenne M. Beach, Monica N. Benjamin, Charles I. Berul, Bryan Cannon, Frank Cecchin, Mitchell I. Cohen, Aarti S. Dalal, Brynn E. Dechert, Anne Foster, Roman Gebauer, M. Cecilia Gonzalez Corcia, Prince J. Kannankeril, Peter P. Karpawich, Jeffery J. Kim, Mani Ram Krishna, Peter Kubuš, Martin J. LaPage, Douglas Y. Mah, Lindsey Malloy-Walton, Aya Miyazaki, Kara S. Motonaga, Mary C. Niu, Melissa Olen, Thomas Paul, Eric Rosenthal, Elizabeth V. Saarel, Massimo Stefano Silvetti, Elizabeth A. Stephenson, Reina B. Tan, John Triedman, Nicholas H. Von Bergen, Philip L. Wackel, Philip M. Chang, Fabrizio Drago, Anne M. Dubin, Susan P. Etheridge, Apichai Kongpatanayothin, Jose Manuel Moltedo, Ashish A. Nabar, and George F. Van Hare
- Subjects
RCT, randomized clinical trial ,Lead removal ,PACES ,HCM, hypertrophic cardiomyopathy ,Arrhythmogenic cardiomyopathy ,COR, class of recommendation ,LQTS, long QT syndrome ,Sports and physical activity ,030204 cardiovascular system & hematology ,Pediatrics ,TTM, transtelephonic monitoring ,0302 clinical medicine ,Insertable cardiac monitor ,Implantable cardioverter defibrillator ,LVEF, left ventricular ejection fraction ,VT, ventricular tachycardia ,Genetic arrhythmias ,030212 general & internal medicine ,LMIC, low- and middle-income countries ,Children ,Transvenous ,IPE, in-person evaluation ,Cardiac channelopathies ,Low- and middle-income countries ,LGE, late gadolinium enhancement ,BrS, Brugada syndrome ,Antitachycardia pacing ,Neuromuscular disease ,Ambulatory ECG monitoring ,Hypertrophic cardiomyopathy ,3. Good health ,Pacemaker ,Echocardiography ,Catecholaminergic polymorphic ventricular tachycardia ,Cardiac transplantation ,CPVT, catecholaminergic polymorphic ventricular tachycardia ,VF, ventricular fibrillation ,Long QT syndrome ,RIM, remote interrogation and monitoring ,Cardiology and Cardiovascular Medicine ,Atrioventricular block ,MR imaging ,Cardiomyopathy ,ACM, arrhythmogenic cardiomyopathy ,Sick sinus syndrome ,Heart failure ,ARVC, arrhythmogenic right ventricular cardiomyopathy ,Syncope ,Endocardial lead ,Heart block ,03 medical and health sciences ,Sudden cardiac arrest ,LOE, level of evidence ,Physiology (medical) ,Bradycardia ,Brugada syndrome ,Ventricular fibrillation ,Postoperative ,ICD, implantable cardioverter defibrillator ,Antiarrhythmic drug therapy ,SCA, sudden cardiac arrest ,Shared decision-making ,Congenital heart disease ,CCAVB, congenital complete atrioventricular block ,Practical Guideline ,ICM, insertable cardiac monitor ,NIDCM, nonischemic dilated cardiomyopathy ,Lead extraction ,Cardiovascular implantable electronic devices ,ECG ,AV, atrioventricular ,Asystole ,Ventricular tachycardia ,SND, sinus node dysfunction ,Epicardial lead ,Sudden cardiac death ,CHD, congenital heart disease ,Remote monitoring ,SCD, sudden cardiac death ,Coronary artery compression ,ECG, electrocardiogram ,Arrhythmogenic right ventricular cardiomyopathy ,CIED, cardiovascular implantable electronic device ,MRI, magnetic resonance imaging ,Expert consensus statement - Abstract
In view of the increasing complexity of both cardiovascular implantable electronic devices (CIEDs) and patients in the current era, practice guidelines, by necessity, have become increasingly specific. This document is an expert consensus statement that has been developed to update and further delineate indications and management of CIEDs in pediatric patients, defined as ≤21 years of age, and is intended to focus primarily on the indications for CIEDs in the setting of specific disease categories. The document also highlights variations between previously published adult and pediatric CIED recommendations and provides rationale for underlying important differences. The document addresses some of the deterrents to CIED access in low- and middle-income countries and strategies to circumvent them. The document sections were divided up and drafted by the writing committee members according to their expertise. The recommendations represent the consensus opinion of the entire writing committee, graded by class of recommendation and level of evidence. Several questions addressed in this document either do not lend themselves to clinical trials or are rare disease entities, and in these instances recommendations are based on consensus expert opinion. Furthermore, specific recommendations, even when supported by substantial data, do not replace the need for clinical judgment and patient-specific decision-making. The recommendations were opened for public comment to Pediatric and Congenital Electrophysiology Society (PACES) members and underwent external review by the scientific and clinical document committee of the Heart Rhythm Society (HRS), the science advisory and coordinating committee of the American Heart Association (AHA), the American College of Cardiology (ACC), and the Association for European Paediatric and Congenital Cardiology (AEPC). The document received endorsement by all the collaborators and the Asia Pacific Heart Rhythm Society (APHRS), the Indian Heart Rhythm Society (IHRS), and the Latin American Heart Rhythm Society (LAHRS). This document is expected to provide support for clinicians and patients to allow for appropriate CIED use, appropriate CIED management, and appropriate CIED follow-up in pediatric patients.
- Published
- 2021
- Full Text
- View/download PDF